BioSpace News Archive

Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda ® , to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo ® ) in the treatment of cancer. Veyonda is a first-in-class sphingosine-1-phosphate inhibitor with h

Xcenda’s FormularyDecisions™, a secure online platform that facilitates the exchange of information between payers and life sciences companies, today announced agreements with the Institute for Clinical and Economic Review (ICER) and AMCP that will provide subscribers expanded access to the clinical evidence and health economic information needed to make data-driven product decisions.

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity

Kadmon Holdings, Inc. announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences

Tonix Pharmaceuticals (NASDAQ:TNXP), will be presenting at this year’s virtual Fall Investor Summit on November 16th-18th.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four investor conferences through the end of the year. Stifel 2020 Virtual Healthcare Conference Monday, November 16, 2020 1:00PM PT/4:00PM ET Jefferies Virtual London Healthcare Conference Tuesday, November 17,

BioMarin Pharmaceutical Inc. announced that management will participate in three upcoming virtual conferences.

Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial1.

Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the successful completion of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for its oral antifungal product candidate oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC)

Cerus Corporation announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in two conferences:.